179 related articles for article (PubMed ID: 18327212)
21. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas.
Richmond A; Fine R; Murray D; Lawson DH; Priest JH
J Invest Dermatol; 1986 Mar; 86(3):295-302. PubMed ID: 3745955
[TBL] [Abstract][Full Text] [Related]
22. Human melanocytes form a PAX3-expressing melanocyte cluster on Matrigel by the cell migration process.
Choi H; Jin SH; Han MH; Lee J; Ahn S; Seong M; Choi H; Han J; Cho EG; Lee TR; Noh M
J Dermatol Sci; 2014 Oct; 76(1):60-6. PubMed ID: 25128984
[TBL] [Abstract][Full Text] [Related]
23. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
[TBL] [Abstract][Full Text] [Related]
24. PAX3 across the spectrum: from melanoblast to melanoma.
Medic S; Ziman M
Crit Rev Biochem Mol Biol; 2009 Jun; 44(2-3):85-97. PubMed ID: 19401874
[TBL] [Abstract][Full Text] [Related]
25. Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease.
Kubic JD; Young KP; Plummer RS; Ludvik AE; Lang D
Pigment Cell Melanoma Res; 2008 Dec; 21(6):627-45. PubMed ID: 18983540
[TBL] [Abstract][Full Text] [Related]
26. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.
Chen PL; Chen WS; Li J; Lind AC; Lu D
Mod Pathol; 2013 Jan; 26(1):44-53. PubMed ID: 22899289
[TBL] [Abstract][Full Text] [Related]
28. PAX3 and SOX10 activate MET receptor expression in melanoma.
Mascarenhas JB; Littlejohn EL; Wolsky RJ; Young KP; Nelson M; Salgia R; Lang D
Pigment Cell Melanoma Res; 2010 Apr; 23(2):225-37. PubMed ID: 20067553
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical profiling including beta-catenin in conjunctival melanocytic lesions.
Reddy HS; Keene CD; Chang SH; Jian-Amadi A; Cimino PJ
Exp Mol Pathol; 2017 Apr; 102(2):198-202. PubMed ID: 28161440
[TBL] [Abstract][Full Text] [Related]
30. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas.
Roesch A; Becker B; Meyer S; Wild P; Hafner C; Landthaler M; Vogt T
Mod Pathol; 2005 Sep; 18(9):1249-57. PubMed ID: 15803180
[TBL] [Abstract][Full Text] [Related]
31. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions.
Sharma BK; Smith CC; Laing JM; Rucker DA; Burnett JW; Aurelian L
Dermatology; 2006; 213(3):192-9. PubMed ID: 17033167
[TBL] [Abstract][Full Text] [Related]
32. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
33. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
34. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
[TBL] [Abstract][Full Text] [Related]
35. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.
Venesio T; Chiorino G; Balsamo A; Zaccagna A; Petti C; Scatolini M; Pisacane A; Sarotto I; Picciotto F; Risio M
Mod Pathol; 2008 Jun; 21(6):716-26. PubMed ID: 18408659
[TBL] [Abstract][Full Text] [Related]
36. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
37. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
Uribe P; Wistuba II; González S
Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284
[TBL] [Abstract][Full Text] [Related]
38. Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity.
He SJ; Stevens G; Braithwaite AW; Eccles MR
Mol Cancer Ther; 2005 Jun; 4(6):996-1003. PubMed ID: 15956257
[TBL] [Abstract][Full Text] [Related]
39. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
Kubic JD; Lui JW; Little EC; Ludvik AE; Konda S; Salgia R; Aplin AE; Lang D
J Biol Chem; 2015 Sep; 290(36):21901-14. PubMed ID: 26205821
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression.
Reed JA; McNutt NS; Albino AP
Am J Pathol; 1994 Feb; 144(2):329-36. PubMed ID: 8311116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
